Insulet Corp.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Ashley McEvoy
- Full Time Employees
- 5,400
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 100 Nagog Park Acton MA United States of America 01720
- IPO Date
- May 15, 2007
- CIK
- 0001145197
- Website
- insulet.com
- Similar Companies
- Business
- Insulet Corporation (NASDAQ: PODD) is a medical device company that designs, develops, manufactures and commercializes innovative tubeless insulin delivery systems and related products primarily for people with diabetes; its flagship Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System, which integrates with continuous glucose monitors for automated insulin dosing via a smartphone app or dedicated controller, the Omnipod DASH Insulin Management System featuring Bluetooth-enabled touchscreen control and waterproof tubeless Pods delivering continuous insulin for up to 72 hours without needles, the Omnipod GO pre-filled disposable Pod system for type 2 diabetes patients requiring basal insulin, and the core Omnipod Insulin Management System offering wearable needle-free delivery; the company also pursues applications of its Pod technology for non-insulin subcutaneous drug delivery in other therapeutic areas through its Drug Delivery segment. Headquartered in Acton, Massachusetts, and founded in 2000, Insulet operates highly automated manufacturing facilities with key geographic presence in the US, Europe, Asia Pacific, the Middle East, Australia and select emerging markets including China and Malaysia, serving approximately 500,000 global customers across 25 countries. In recent developments, the company completed acquisitions of automated insulin delivery assets from Bigfoot Biomedical and Automated Glucose Control LLC for $25 million each to bolster its Omnipod 5 technology, announced a proposed $450 million senior unsecured notes offering due 2033 and amendments to its credit agreement extending revolving credit facility maturity to 2030 with commitments increased to $500 million to redeem its 0.375% Convertible Senior Notes due 2026 including the remaining $380 million principal, integrated Omnipod 5 with Dexcom G7 in multiple European markets alongside new CGM reimbursements in Norway, extended its supply agreement with NXP USA effective 2025 for critical manufacturing components, redeemed outstanding convertible notes, and raised its fiscal 2025 revenue growth guidance to 28-29% at constant currency while outlining a long-term strategy targeting 20% revenue CAGR through 2028 driven by global expansion, operational efficiencies and innovation.
PODD Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Insulet Corporation
PODD Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Insulet Corporation
PODD Investors Have Opportunity to Lead Insulet Corporation Securities Fraud Lawsuit with the Schall Law Firm
PODD Investors Have Opportunity to Lead Insulet Corporation Securities Fraud Lawsuit with the Schall Law Firm
Bronstein, Gewirtz & Grossman LLC Urges Insulet Corporation Investors to Act: Class Action Filed Alleging Investor Harm
Grabar Law Office Investigates Claims on Behalf of Shareholders of Insulet Corporation (PODD)
Insulet Corporation: A High-Quality Growth Story Trading At A Reasonable PEG
Pomerantz Law Firm Announces the Filing of a Class Action Against Insulet Corporation and Certain Officers - PODD
Law Offices of Howard G. Smith Encourages Insulet Corporation (PODD) Shareholders to Inquire About Securities Fraud Class Action
Investor Notice: Robbins LLP Informs Investors of the Insulet Corporation Securities Class Action Lawsuit
Insulet to Announce Second Quarter 2026 Financial Results on August 5, 2026
Do Options Traders Know Something About Insulet Stock We Don't?
Here's Why Insulet (PODD) is a Strong Momentum Stock
Insulet (PODD) Just Overtook the 50-Day Moving Average
Insulet Announces Appointment of Jonathan J. Mazelsky to its Board of Directors
Why Insulet (PODD) is a Top Growth Stock for the Long-Term
This Insulet Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Insulet Corporation (PODD) Discusses Recent Product Recalls and Physician Community Response at ADA Meeting Transcript
Why Insulet (PODD) is a Top Momentum Stock for the Long-Term
Insulet Corporation Valuation Pressure Has Dropped Enough (Upgrade)